Eurofins Clinical Diagnostics laboratories have been supporting the pharmaceutical industry for many years with specialty diagnostics tests to identify patients that can benefit from particular treatments. Working together with pharmaceutical organisations and companies  from the inception of the drug discovery phase to develop a companion or a complementary diagnostics tests translates in:

-Increased drug efficiency, targeting only those patients that are most likely to benefit from the treatment.

-Better drug safety profiles, through the identification of patients that are at risk of severe adverse side effects and allowing for dose adjustment or drug discontinuation when necessary.

-Personalised treatment thanks to therapeutic drug monitoring which allows for the modification of drug administration and/or dose when required.

Clinical diagnostic tests allow the classification of patients depending on their genetic and metabolic profiles, thus aiding the adjustment of drug dosage in a personalized manner. Consequently, this reduces undesirable side effects and toxicity. This new approach translates into safer drug profiles facilitating the drug approval process and reducing time to market.